CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 79 enrolled
Drug / intervention
acetylsalicylic acid +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00468910
NCT00468910Phase 2Completed

Spectral Markers in Aspirin Chemoprevention of Colonic Neoplasia

National Cancer Institute (NCI)·interventional·Posted May 3, 2007·Updated May 31, 2017

In Brief

A Phase 2 clinical trial evaluating acetylsalicylic acid, placebo, and 1 other intervention for Colon Cancer and 2 related conditions. Completed, enrolled 79 participants across 1 site.

Detailed Summary

This randomized phase II trial is studying how well aspirin works in preventing colorectal cancer in patients at increased risk of colorectal cancer. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of aspirin may prevent colorectal cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 3, 2007
Enrollment StartMar 1, 2007
Primary CompletionDec 1, 2009
Study CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 19.2 years ago

Interventions

acetylsalicylic aciddrug

Given orally

placebodrug

Given orally

laboratory biomarker analysisother

Correlative study